Europe’s drug launch pace is reportedly slowing after he US introduced its “most favored nation” (MFN) drug pricing policy
According to the article, an analysis by Globaldata finds that the number of new medicine launches across Europe has fallen by about 35% in the 10 months since the US introduced its most favored nation (MFN) pricing policy.
In Denmark, the article states launches are estimated to have dropped from 60 to 48 compared with the previous 10 months.
The implications from The Danish Association of the Pharmaceutical Industry (LIF) point of view
- fewer and later launches could reduce patient access to innovative medicines
- Denmark’s role as a reference country may make companies more cautious about launching at low prices if it affects US revenues
What LIF is calling for
- lifting the economic framework for medicines and thereby showing higher willingness to pay
- higher political prioritisation and a long-term national investment target of innovative treatments
- Danish leadership on an ambitious EU-focused industrial policy strategy for medicines
Read more at https://www.lif.dk/lif-advarer-laegemidlerne-kommer-senere-til-europa-og-danmark/
